Skip to main content

Table 4 Insulin preparations (Cold-chain)

From: Evaluating the effect of a proposed logistics fee cap on pharmaceuticals in South Africa - a pre and post analysis

     Pre-Logistics Fee Regulation Prices Post-Logistics Fee Regulation Prices   
Active Ingredients O/G Pack Size & Quantity Ex- Man.Price in 2013 Log Fee in 21013 SEP in 2013 (VAT incl.) Unit Price in 2013 Logistics fee/SEP % Logistics fee with proposed cap SEP with proposed cap (VAT incl.) Unit Price with proposed cap Logistics fee with proposed cap/Sep % Change in SEP after logistics fee cap Overall effect on SEP after logistics fee cap
Ultra-fast acting
Insulin Glulisine O 10/1 258.79 8 304.14 30.41 2.63 19.53 317.28 31.73 6.15 13.14 Increase
Insulin aspart O 10/1 223.63 30.19 289.36 28.94 10.44 17.42 274.79 27.48 6.34 −14.57 Decrease
Insulin Lispro O 10/1 210.08 12.60 253.86 25.39 4.97 16.60 258.42 25.84 6.43 4.5694 Increase
Fast acting
Insulin (Dna) O 10/1 193.64 26.14 250.56 25.06 10.43 15.62 238.56 23.86 6.55 −11.99 Decrease
Human Insulin G 5/1 240.25 19.22 295.79 59.16 6.49 18.41 294.87 58.97 6.244 −0.92 Decrease
Regular Human Insulin (Rdna) O 10/1 210.08 12.60 253.86 25.39 4.97 16.60 258.42 25.84 6.43 4.56 Increase
Intermediate to long acting
Human Insulin G 5/1 240.25 19.22 295.79 59.16 6.49 18.41 294.87 58.97 6.244 −0.92 Decrease
Isophane insulin O 10.1 233.46 31.52 302.07 30.21 10.43 18.01 286.67 28.67 6.28 −15.40 Decrease
Isophane Human Insulin (Rdna) O 10/1 237.81 14.27 287.37 28.74 4.97 18.27 291.93 29.19 6.26 4.56 Increase
Long acting Insulin analogues
Insulin Glargine O 3/5 505.68 23.83 603.64 40.24 3.95 25.23 605.23 40.35 4.17 1.59 Increase
Insulin Detemir O 3/5 460.73 62.19 596.14 39.74 10.43 31.64 561.30 37.42 5.64 −34.83 Decrease
Biphasic
Biosynthetic human insulin O 3/5 458.27 61.87 592.96 39.53 10.44 31.49 558.34 37.22 5.64 −34.61 Decrease
Biosynthetic Human Insulin (30 % Regular Insulin and 70 % Isophane Insulin) O 3/5 349.13 22.29 423.41 28.23 5.26 24.95 426.45 28.43 5.85 3.04 Increase
Insulin (Human) G 3/5 321.71 15.28 384.17 25.61 3.98 23.30 393.31 26.22 5.92 9.14 Increase
Human Insulin/ isophane insulin G 5/1 235.21 18.82 289.59 57.92 6.49 18.11 288.79 57.76 6.27 −0.80 Decrease
Biphasic Insulin analogues
75 % Insulin Lispro Protamine Suspension (Npl) O 3/5 349.12 22.28 423.39 28.23 5.26 24.95 426.43 28.43 5.85 3.04 Increase
Insulin aspart O 3/5 417.34 56.34 539.99 35.99 10.43 29.040 508.87 33.92 5.71 −31.12 Decrease
50 % Insulin Lispro Protamine Suspension (Npl) O 3/5 349.12 22.28 423.39 28.23 5.26 24.95 426.43 28.43 5.85 3.04 Increase
  1. All Prices are in ZAR; O = Originator brand; G = Generic brand; Originator insulin preparations: P value = 0.148; Generic insulin preparations: P value = 0.808
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us